Interchangeable Biosimilars: Key Points for Patients

Extrapolating Indications

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      SPEAKER
      Jonathan Kay picture

      Jonathan Kay, MD
      UMass Memorial Health
      Worcester, MA

      Jonathan Kay, MD, defines biosimilarity and the necessary requirements for that designation and discusses the implications of interchangeability on patient access to biological products.

      ©2022 Boehringer Ingelheim Inc. All Rights Reserved. SC-US-74798 11/22